Maternal serum placental growth factor in prospective screening for aneuploidies at 8–13 weeks’ gestation
Fetal Diagnosis and Therapy, 04/10/2012Pandya P et al.
Inclusion of serum PLGF improves the performance of the first–trimester combined test in screening for trisomy–21.
In singleton pregnancies attending for routine care, serum PLGF, free β–hCG and PAPP–A were measured at 8+0–13+6 weeks’ gestation, and fetal NT was measured at 11+0–13+6 weeks.
The population included 12,154 normal and 44 trisomy–21 pregnancies.
Authors examined the effect of adding PLGF on the performance of screening by the combined test.
In the trisomy–21 pregnancies the median multiple of the normal median PLGF, adjusted for gestational age, maternal weight, racial origin, smoking status and method of conception, was significantly reduced (0.6070, 95% CI 0.5543–0.6648), and this did not change significantly with gestational age.
Adding PLGF to combined testing with a risk cut–off of 1 in 100 reduced the false positive rate from 2.7% (95% CI 2.5–3.0) to 2.6% (95% CI 2.4–2.8) and increased the detection rate from 85% (95% CI 75–93) to 88% (95% CI 78–95).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.